# Difference Between Relapsing Ms and Progressive Ms Author: Nex Virox Team (Editorial Team) Reviewed by: Varshal Nirbhavane Published: 2026-09-05 Last updated: 2026-09-05 Canonical: https://nexvirox.com/difference-between/difference-between-relapsing-and-progressive-ms/ **Quick answer:** The main difference between Relapsing Ms and Progressive Ms is that relapsing MS features distinct attacks with full recovery between episodes, while progressive MS involves steady, worsening disability from onset. Relapsing Ms is defined by unpredictable flare-ups followed by remission, while Progressive Ms is defined by continuous neurological decline without clear relapses.

Difference Between Relapsing Ms and Progressive Ms: Comparison Table

Aspect	Relapsing Ms	Progressive Ms
Definition	Characterized by acute neurological attacks followed by periods of full or partial recovery.	Defined by steadily worsening neurological function with accumulation of disability over time.
Core Mechanism	Focal inflammatory demyelinating lesions cause discrete attacks that may remit as inflammation subsides.	Diffuse axonal loss and progressive neurodegeneration drive continuous decline independent of acute inflammation.
Disease Course	Relapses and remissions alternate unpredictably, with stable function between distinct flare-ups.	Neurological function worsens steadily, occasionally with plateaus but without true remission phases.
Onset Pattern	Typically begins with an acute episode such as optic neuritis or limb numbness in younger adults.	Often starts gradually with walking difficulty or subtle cognitive changes, frequently at older ages.
Age of Onset	Most commonly diagnosed between ages 20 and 40 years.	Primary progressive form typically begins around age 40 to 50 years.
Sex Ratio	Affects women roughly two to three times more often than men.	Sex distribution is more balanced, with a smaller female predominance.
Relapse Frequency	Patients average one relapse every one to two years without treatment.	Distinct relapses are rare or absent; progression defines the clinical picture.
Disability Progression	Disability accumulates mainly from incomplete recovery after repeated relapses.	Disability accrues continuously from onset, independent of discrete attacks.
Inflammatory Activity	Gadolinium-enhancing lesions on MRI indicate active focal inflammation during relapses.	MRI shows fewer enhancing lesions but greater brain atrophy and normal-appearing white matter damage.
MRI Findings	Multiple well-defined T2 hyperintense lesions, often periventricular, with active enhancement.	Diffuse atrophy, fewer new lesions, and more extensive spinal cord involvement.
Disease Modifying Therapies	Over 15 approved DMTs effectively reduce relapse rates and new lesion formation.	Only ocrelizumab and siponimod show modest efficacy in slowing disability progression.
Treatment Response	Inflammation-targeting drugs reduce relapse frequency by approximately 50 to 70 percent.	Available therapies slow progression modestly but do not halt neurodegeneration.
Primary Progressive Form	Not applicable; relapsing MS never presents as primary progressive from onset.	PPMS shows progression from symptom onset without preceding relapses or remissions.
Secondary Progressive Form	Many relapsing patients transition to secondary progressive MS after 10 to 20 years.	SPMS follows an initial relapsing phase then enters steady progression without relapses.
Diagnostic Criteria	Requires dissemination in time and space with at least one clinical attack.	Requires one year of disability progression plus two of three MRI criteria.
Biomarker Utility	Oligoclonal bands in CSF support diagnosis but do not predict relapse timing.	Neurofilament light chain levels correlate with ongoing axonal damage and progression.
Walking Speed	Gait often normal between relapses; timed 25-foot walk may be preserved.	Timed 25-foot walk worsens measurably year over year in most patients.
Cognitive Impact	Cognitive deficits occur during relapses but may improve with recovery.	Processing speed and memory decline steadily, affecting daily function progressively.
Fatigue Pattern	Fatigue spikes during relapses and often lessens during remission periods.	Fatigue is persistent and constant, worsening as neurological function declines.
Lesion Location	Lesions concentrate in optic nerves, brainstem, cerebellum, and periventricular white matter.	Cortical and spinal cord involvement dominates, with less periventricular predilection.
Axonal Loss Rate	Axonal damage occurs secondary to acute inflammatory demyelination.	Axonal loss proceeds from earliest stages, driven by primary neurodegeneration.
Prognosis Timeline	Untreated patients reach Expanded Disability Status Scale 6 after about 15 to 20 years.	Untreated patients reach EDSS 6 approximately 8 to 10 years after onset.
Treatment Cost	Annual DMT costs range from $60,000 to $90,000 in the United States.	Approved therapies carry similar annual costs with fewer available options.
Monitoring Frequency	Neurology visits and MRI scans typically occur every 6 to 12 months.	Clinical assessments every 3 to 6 months track functional decline more closely.
Rehabilitation Role	Physical therapy during recovery helps restore function after acute attacks.	Ongoing rehabilitation maintains mobility and independence as function declines.
Typical Patient Profile	Younger adults, predominantly female, with episodic sensory or visual symptoms.	Older adults, more balanced sex ratio, with progressive gait and bladder dysfunction.
Response to Steroids	High-dose corticosteroids shorten relapse duration and speed functional recovery.	Steroids provide no benefit for progressive disability accumulation.
Research Focus	Trials target reducing relapse frequency and new MRI lesion formation.	Research investigates neuroprotection, remyelination, and metabolic support strategies.
Quality of Life	Quality of life fluctuates with relapse status but stabilizes during remission.	Quality of life declines progressively as mobility, cognition, and independence diminish.
Best-Fit Scenario	Best for patients with active inflammatory disease who respond to immunomodulatory therapy.	Best for patients with gradual neurodegeneration where preserving function is the primary goal.

What Is Relapsing Ms?

Relapsing MS is the most common form of multiple sclerosis, marked by clear attacks of new symptoms followed by periods of full or partial recovery. It drives disability accumulation through acute inflammatory episodes rather than steady decline.

Definition of Relapsing Ms

Relapsing MS is a clinical course of multiple sclerosis defined by discrete, acute neurological episodes lasting at least 24 hours, separated by periods of stability. Each attack results from active central nervous system inflammation, and recovery between episodes varies widely.

Key Characteristics of Relapsing Ms

Characteristic	What It Means in Practice
Acute attacks	Symptoms appear suddenly over days, then plateau before any improvement begins.
Recovery phases	Function often returns partially or fully between episodes, though residual deficits may remain.
Inflammatory lesions	Active white matter lesions visible on MRI scans correspond directly to clinical attack events.
Age of onset	Typically diagnosed between ages 20 and 40, younger than most progressive forms.
Relapse frequency	Attack rate averages roughly one per year, but individual patterns vary enormously.
Treatment response	Disease-modifying therapies substantially reduce attack frequency and new lesion formation.
Disability trajectory	Disability accumulates stepwise, worsening with each relapse rather than continuously.
Sex distribution	Affects women two to three times more often than men, unlike progressive forms.
Trigger sensitivity	Infections, stress, and postpartum states can provoke or precede new clinical attacks.
MRI activity	Gadolinium-enhancing lesions confirm active inflammation at the moment of scanning.

Common Examples of Relapsing Ms

Optic neuritis – painful vision loss in one eye that qualifies as a classic first demyelinating attack.
Lhermitte sign – electric shock sensation down the spine on neck flexion, indicating cervical cord lesion.
Internuclear ophthalmoplegia – impaired horizontal eye movement causing double vision, highly specific to MS.
Transverse myelitis – bilateral limb weakness and sensory loss from a single spinal cord inflammatory episode.
Uhthoff phenomenon – temporary worsening of existing symptoms when body temperature rises from exercise or heat.
Trigeminal neuralgia – severe facial pain attacks that respond to MS-specific treatments rather than standard neuralgia drugs.
Clinically isolated syndrome – first neurological episode that meets criteria for high risk of future relapses.
Radiologically isolated syndrome – MRI findings suggestive of MS in someone who has never experienced clinical symptoms.
McArdle syndrome – painful tonic spasms and dysarthria triggered by voluntary movement, a rare but recognised relapse presentation.
Acute cerebellar ataxia – sudden loss of coordination and balance from inflammatory demyelination in the cerebellum.

Advantages and Limitations of Relapsing Ms

Advantages	Limitations
Disease-modifying therapies reduce relapse rates by roughly half or more in most patients.	Every relapse carries risk of permanent residual disability that never fully resolves.
Long periods of stability allow many patients to maintain full employment and normal daily routines.	Attack unpredictability creates constant anxiety about when the next episode will strike.
MRI monitoring gives clinicians a reliable early signal of treatment failure before symptoms worsen.	Some patients experience incomplete recovery, leaving cumulative deficits after each successive attack.
Relapsing course responds well to steroid pulse therapy for rapid symptom resolution during acute episodes.	Steroid side effects including insomnia, mood swings, and glucose elevation limit repeated use.
Younger onset means patients often have more years of preserved neurological reserve to draw upon.	Many patients eventually transition to secondary progressive MS, losing the relapsing treatment advantage.
Clear clinical endpoints make clinical trial participation and treatment efficacy measurement straightforward.	Highly active relapsing disease can cause rapid disability accumulation despite optimal available therapy.
Pregnancy often reduces relapse frequency, particularly in the third trimester, offering natural respite.	Postpartum period carries sharply increased relapse risk that requires careful planning.
Numerous approved therapies allow personalised switching when one drug fails or causes side effects.	All current disease-modifying therapies carry risks of infection, injection site reactions, or organ toxicity.
Relapsing MS patients typically retain cognitive function longer than those with progressive onset forms.	Treatment costs remain extremely high, creating access barriers even in wealthy healthcare systems.
Clear inflammatory biomarkers help clinicians distinguish active disease from pseudo-relapses with confidence.	Pseudo-relapses from infection or heat can mimic true attacks, leading to unnecessary steroid exposure.

What Is Progressive Ms?

Progressive Ms is a form of multiple sclerosis where neurological disability steadily worsens over time. It exists because the immune system continuously damages the central nervous system. Unlike relapsing forms, progressive Ms lacks distinct recovery periods between attacks.

Definition of Progressive Ms

Progressive Ms is a clinical course of multiple sclerosis characterised by continuous, irreversible accumulation of neurological disability from onset, with or without occasional plateaus or minor temporary improvements. It involves ongoing neurodegeneration rather than discrete inflammatory episodes followed by remission.

Key Characteristics of Progressive Ms

Characteristic	What It Means in Practice
Steady decline	Neurological function worsens gradually over months and years without clear relapses.
No remissions	Symptoms do not fully resolve; disability accumulates continuously without recovery phases.
Spinal cord involvement	Progressive walking difficulty and stiffness frequently appear earlier than in relapsing forms.
Older onset age	Typically diagnosed between ages 40 and 60, later than relapsing-remitting Ms.
Equal sex ratio	Progressive Ms affects men and women more equally than relapsing forms.
Fewer brain lesions	MRI often shows fewer enhancing lesions but more spinal cord and brain atrophy.
Less inflammation	Disease activity is driven more by neurodegeneration than by acute inflammatory attacks.
Poorer treatment response	Disease-modifying therapies are generally less effective for progressive forms.
Primary vs secondary	Primary progressive Ms progresses from onset; secondary progressive follows relapsing Ms.
Disability milestones	Walking aids or wheelchair use often become necessary within 10 to 15 years.

Common Examples of Progressive Ms

Primary progressive Ms - progresses from the very first symptom without any preceding relapses or remissions.
Secondary progressive Ms - develops after an initial relapsing-remitting phase, then disability steadily accumulates.
Progressive-relapsing Ms - steady decline from onset with occasional acute relapses superimposed on the progression.
Spinal progressive Ms - predominantly affects the spinal cord, causing early gait and bladder dysfunction.
Cerebral progressive Ms - involves significant cognitive decline and brain atrophy with fewer spinal symptoms.
Active progressive Ms - shows new MRI lesions or clinical relapses alongside continuous disability progression.
Non-active progressive Ms - disability worsens without new lesions or relapses on repeated MRI scans.
Early-onset progressive Ms - diagnosed before age 40, often with faster disability accumulation than typical cases.
Late-onset progressive Ms - begins after age 60, frequently with predominantly motor symptoms and rapid decline.
Tumefactive progressive Ms - large tumour-like lesions on MRI that contribute to progressive neurological deficits.

Advantages and Limitations of Progressive Ms

Advantages	Limitations
Predictable trajectory allows realistic long-term planning for care needs.	No approved therapy halts progression; most treatments only slow disability modestly.
Fewer acute attacks means less unpredictable hospitalisation and emergency steroid use.	Continuous decline often leads to permanent mobility loss requiring walking aids or wheelchairs.
Clearer disease course simplifies discussions about prognosis with patients and families.	Bladder, bowel and sexual dysfunction become persistent problems that resist treatment.
Stable symptoms may allow better adaptation to daily living routines over time.	Cognitive impairment progresses silently, affecting memory, processing speed and decision-making.
Less frequent MRI monitoring may be needed compared to highly active relapsing forms.	Fatigue and pain are chronic and often worsen, significantly reducing quality of life.
Clinical trials for progressive Ms receive substantial research funding and attention.	Many disease-modifying drugs approved for relapsing Ms show no benefit in progressive forms.
Patients may qualify for disability benefits earlier due to consistent functional decline.	Life expectancy is reduced by roughly 7 to 14 years compared to the general population.
Spasticity management can improve with consistent physiotherapy and medication adjustments.	Depression and anxiety rates are high due to relentless progression without hope of remission.
Fewer relapses reduce cumulative steroid exposure and associated side effects.	Swallowing and breathing difficulties emerge in advanced stages, requiring complex care.
Diagnosis is often clearer because symptoms follow a steadily worsening pattern.	Caregiver burden grows continuously as physical dependence increases without recovery periods.

Similarities Between Relapsing Ms and Progressive Ms

Shared Aspect	How Relapsing Ms and Progressive Ms Are Alike
Disease Category	Relapsing Ms and Progressive Ms are both autoimmune demyelinating diseases of the central nervous system.
Core Mechanism	Relapsing Ms and Progressive Ms both involve immune-mediated damage to the myelin sheath around nerves.
Primary Target	Relapsing Ms and Progressive Ms both attack the brain and spinal cord tissues.
Diagnostic Tool	Relapsing Ms and Progressive Ms both require MRI scans to identify lesions and confirm diagnosis.
Diagnostic Criteria	Relapsing Ms and Progressive Ms both use the McDonald criteria for clinical classification.
Specialist Involved	Relapsing Ms and Progressive Ms both require care from a neurologist specializing in multiple sclerosis.
Patient Population	Relapsing Ms and Progressive Ms both predominantly affect adults between twenty and fifty years old.
Gender Ratio	Relapsing Ms and Progressive Ms both occur more frequently in women than in men.
Symptom Variety	Relapsing Ms and Progressive Ms both cause fatigue, numbness, weakness, and vision problems.
Bladder Impact	Relapsing Ms and Progressive Ms both commonly cause urinary urgency and incontinence issues.
Cognitive Effects	Relapsing Ms and Progressive Ms both produce memory and concentration difficulties in patients.
Mobility Limitation	Relapsing Ms and Progressive Ms both impair walking ability and physical coordination over time.
Pain Experience	Relapsing Ms and Progressive Ms both generate neuropathic pain and muscle spasticity.
Disease Management	Relapsing Ms and Progressive Ms both require ongoing symptomatic treatment and regular monitoring.
Lifestyle Adjustment	Relapsing Ms and Progressive Ms both require patients to manage stress and maintain rest.
Physical Therapy	Relapsing Ms and Progressive Ms both benefit from physiotherapy to preserve muscle function.
Relapse Treatment	Relapsing Ms and Progressive Ms both use corticosteroids to manage acute flare-up episodes.
Medication Route	Relapsing Ms and Progressive Ms both use injectable or oral disease-modifying therapies.
Monitoring Frequency	Relapsing Ms and Progressive Ms both need regular neurological exams every six months.
Prognosis Variable	Relapsing Ms and Progressive Ms both show unpredictable progression rates across different patients.
Disability Scale	Relapsing Ms and Progressive Ms both use the Expanded Disability Status Scale for assessment.
Quality Impact	Relapsing Ms and Progressive Ms both significantly reduce overall quality of life.
Emotional Toll	Relapsing Ms and Progressive Ms both increase risks of depression and anxiety.
Support Need	Relapsing Ms and Progressive Ms both require strong family and caregiver support systems.
Heat Sensitivity	Relapsing Ms and Progressive Ms both worsen with increased body temperature or heat exposure.
Fatigue Factor	Relapsing Ms and Progressive Ms both cause debilitating fatigue that affects daily function.
Research Focus	Relapsing Ms and Progressive Ms both are targets of ongoing neuroprotective clinical trials.
Treatment Goal	Relapsing Ms and Progressive Ms both aim to slow disease activity and preserve function.
Lifelong Condition	Relapsing Ms and Progressive Ms both are chronic conditions requiring lifelong medical care.
No Cure	Relapsing Ms and Progressive Ms both currently have no definitive cure available.

Relapsing Ms or Progressive Ms: Which Should You Choose?

You do not choose between these conditions; your disease course chooses for you. The single variable that decides it is whether you experience distinct, recoverable attacks (relapsing) or a steady, irreversible decline without clear flare-ups (progressive). Your neurologist confirms this through MRI activity and symptom history.

When to Use Relapsing Ms

Choose Relapsing Ms when you have clear, separate attacks followed by full or partial recovery. This diagnosis fits if your MRI shows new lesions appearing between episodes, and you respond to disease-modifying therapies that target inflammation. Most people receive this diagnosis first, typically between ages 20 and 40.

When to Use Progressive Ms

Choose Progressive Ms when your disability worsens steadily over at least six months without distinct relapses. This fits if you experience gradual walking difficulty, cognitive decline, or coordination loss from onset, or if your relapsing form transitions into continuous progression. It typically begins after age 40 and responds less to standard anti-inflammatory drugs.

Common Misconceptions About Relapsing Ms and Progressive Ms

Common Myth	The Reality
Relapsing MS and progressive MS are completely different diseases with no shared features.	Both relapsing MS and progressive MS are forms of the same underlying autoimmune demyelinating disease, just with different clinical courses.
Progressive MS always starts as relapsing MS, so every patient eventually progresses.	Progressive MS can begin as primary progressive MS from onset, but not every person with relapsing MS ever transitions to a progressive phase.
Relapsing MS means the disease is mild, while progressive MS always means severe disability.	Relapsing MS can cause severe cumulative disability from attacks, while some progressive MS patients maintain function for many years.
If you have relapsing MS, you will definitely develop progressive MS within ten years.	Approximately half of relapsing MS patients transition to secondary progressive MS within 15-20 years, but many others do not.
Progressive MS has no relapses at all, so symptoms never flare up.	Progressive MS patients can still experience occasional relapses or superimposed attacks on top of steady worsening.
Relapsing MS only affects young women, while progressive MS only affects older men.	Relapsing MS is more common in younger women, but progressive MS affects both sexes and can occur at any adult age.
Progressive MS means you are immediately wheelchair-bound and cannot live independently.	Many progressive MS patients remain ambulatory for decades, and disability progression varies widely from person to person.
Relapsing MS attacks are always visible to others as physical symptoms like walking problems.	Relapsing MS attacks frequently involve invisible symptoms such as fatigue, cognitive fog, numbness, or vision issues that others cannot see.
Progressive MS is simply relapsing MS with more frequent and severe attacks.	Progressive MS is defined by steady neurologic worsening between attacks, not by the frequency or severity of relapses.
You can tell whether someone has relapsing MS or progressive MS just by looking at their MRI scans.	MRI patterns differ on average, but relapsing MS and progressive MS can show overlapping lesion burdens, so clinical history is essential for diagnosis.
Relapsing MS patients never experience gradual worsening between their attacks.	Some relapsing MS patients accumulate disability during incomplete recovery from attacks, even without new acute relapses.
Progressive MS is always inherited, so family history guarantees you will get it.	Progressive MS has a genetic risk component, but most cases occur without any family history of the disease at all.
Relapsing MS is curable with modern medications, so attacks will stop completely.	Disease-modifying therapies reduce relapse frequency in relapsing MS, but they do not cure the disease or eliminate all attacks.
Progressive MS does not respond to any treatment, so medication is completely pointless.	Ocrelizumab and siponimod can slow disability progression in certain progressive MS forms, though they do not reverse existing damage.
Relapsing MS is diagnosed only after a single episode of symptoms like numbness or tingling.	Relapsing MS diagnosis typically requires dissemination in time and space, meaning multiple episodes or MRI lesions at different times and locations.
Progressive MS patients never have inflammation, so anti-inflammatory drugs are useless for them.	Progressive MS involves both neurodegeneration and chronic inflammation, which is why some anti-inflammatory therapies show partial benefit.
Relapsing MS always begins with optic neuritis as the very first symptom.	Relapsing MS can first present with sensory, motor, cerebellar, or bowel/bladder symptoms, not just vision problems.
Progressive MS is a faster killer, so life expectancy is dramatically shortened.	Both relapsing MS and progressive MS reduce life expectancy by only about 5-7 years on average compared to the general population.
Relapsing MS patients are fine between attacks, so they need no ongoing medical care.	Relapsing MS patients require continuous monitoring and treatment because silent MRI activity and subtle worsening can occur between clinical attacks.
Progressive MS means your cognitive abilities will definitely decline to dementia levels.	Cognitive impairment occurs in some progressive MS patients, but many retain normal memory and thinking skills throughout their lives.
Relapsing MS is caused by stress, so relaxing more will cure your disease.	Stress may trigger relapses in relapsing MS, but it is not the root cause, and relaxation cannot cure the underlying autoimmune process.
Progressive MS patients cannot work, drive, or maintain relationships at all.	Many progressive MS patients continue working with accommodations, drive adapted vehicles, and sustain fulfilling personal relationships.
Relapsing MS requires immediate aggressive chemotherapy for every newly diagnosed patient.	Treatment for relapsing MS is individualized based on attack frequency and severity, so not everyone needs high-efficacy therapy right away.
Progressive MS is just the natural end stage that every relapsing MS patient reaches eventually.	Secondary progressive MS follows relapsing-remitting MS in some patients, but primary progressive MS is distinct and not a universal end stage.
Relapsing MS attacks are always painful, so absence of pain means the disease is inactive.	Relapsing MS attacks can be painless, presenting as weakness or numbness, so lack of pain does not rule out an active relapse.
Progressive MS patients cannot benefit from physical therapy or rehabilitation at any stage.	Rehabilitation and physical therapy improve function and quality of life in progressive MS, even though they cannot halt disease progression.
Relapsing MS is a mild disease that never leads to serious disability or wheelchair use.	Untreated relapsing MS can lead to significant disability over time, with about half of patients needing walking aids within 15 years.
Progressive MS is diagnosed only in people over 50, so younger adults never get it.	Primary progressive MS typically onsets around age 40, but younger adults in their 20s and 30s can also receive this diagnosis.
Relapsing MS and progressive MS require exactly the same medications and treatment plans.	Relapsing MS responds to relapse-preventing immunomodulators, while progressive MS often needs different agents targeting progression, so plans differ.
Progressive MS means you will lose all sensation and become completely paralyzed from the neck down.	Progressive MS causes variable disability, but complete paralysis is rare, and many patients retain significant motor function for life.

Conclusion

Difference Between Relapsing Ms and Progressive Ms comes down to disease activity: relapsing MS features clear attacks with recovery periods, while progressive MS steadily worsens without distinct relapses. Choose relapsing treatment for acute flare management. Choose progressive care for continuous symptom and disability management.

## FAQ ### What is the main difference between relapsing MS and progressive MS? Relapsing MS involves sudden attacks of new symptoms followed by recovery periods, while progressive MS features a steady worsening of disability from the onset without distinct relapses. ### Which type of MS is more common, relapsing or progressive? Relapsing MS is far more common, accounting for approximately 85 percent of initial diagnoses, whereas progressive MS is diagnosed in about 10 to 15 percent of patients at onset. ### Is relapsing MS considered safer than progressive MS? Relapsing MS generally has a safer short-term outlook because its symptoms often improve during remission, whereas progressive MS causes continuous neurological decline that accumulates more quickly. ### What are the primary costs associated with treating relapsing versus progressive MS? Relapsing MS treatment costs are typically higher due to expensive disease-modifying therapies, while progressive MS care often shifts toward symptom management and rehabilitation, which can lower medication expenses but raise long-term care costs. ### Can a person switch from relapsing MS to progressive MS? Yes, many people with relapsing MS eventually transition to a secondary progressive phase, where relapses diminish and disability steadily worsens without clear recovery periods. ### How do the symptoms of relapsing MS differ from progressive MS? Relapsing MS symptoms appear suddenly during flare-ups and may resolve, while progressive MS symptoms develop gradually and persist, causing continuous difficulty with walking, balance, and coordination. ### What is a common beginner mistake when comparing relapsing and progressive MS? A common beginner mistake is assuming relapsing MS is always milder, but relapses can cause severe temporary disability, while progressive MS often leads to permanent impairment without acute attacks. ### Are the terms relapsing MS and progressive MS interchangeable? No, the terms are not interchangeable because they describe distinct disease courses with different patterns of symptom activity, disability progression, and treatment approaches. ### Which type of MS responds better to disease-modifying therapies? Relapsing MS responds significantly better to disease-modifying therapies because these drugs target inflammatory relapses, whereas progressive MS has fewer approved treatments and shows limited response to them. ### Can someone with progressive MS experience relapses like relapsing MS patients? No, progressive MS patients typically do not experience distinct relapses, though they may have temporary symptom fluctuations, but the underlying disability continues to worsen steadily over time.